University at Buffalo (UB)
Updated January 18, 2019 This content is archived.
New research by Steven Lipshultz, MD, A. Conger Goodyear Professor and chair of the Department of Pediatrics, showed that exposure to a common drug for attention deficit hyperactivity disorder isn’t likely to increase cardiovascular risk in healthy children, according to a new study involving primates. “The findings are very reassuring in that even high-dose chronic MPH stimulant therapy did not result in any evidence of abnormal structures or function in the hearts of the monkeys,” he said.